Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer
Solventum (NYSE: SOLV) has appointed Dr. Ryan Egeland, MD, as its new Chief Medical Officer. Dr. Egeland will lead the Global Medical and Clinical Affairs team, focusing on enhancing the voice of clinicians and patients, fostering industry collaboration, and identifying innovation opportunities. He brings over 20 years of experience in research, surgery, and executive roles, most recently serving as CEO of Crossfire Medical.
Dr. Egeland's extensive background includes leadership positions at Cardiovascular Systems, Inc., Medtronic, Covidien, and ev3. He holds an M.D. from Harvard Medical School, a Ph.D. and M.B.A. from the University of Oxford as a Rhodes Scholar, and trained in plastic and reconstructive surgery at Northwestern Memorial Hospital. Solventum aims to leverage Dr. Egeland's expertise to advance its innovation pipeline and improve patient care globally.
Solventum (NYSE: SOLV) ha nominato il nuovo Chief Medical Officer, Dr. Ryan Egeland, MD. Il Dr. Egeland guiderà il team delle Affari Medici e Clinici Globali, concentrandosi sul miglioramento della voce dei clinici e dei pazienti, promuovendo la collaborazione nel settore e identificando opportunità di innovazione. Porta con sé oltre 20 anni di esperienza nella ricerca, nella chirurgia e in ruoli esecutivi, avendo recentemente ricoperto il ruolo di CEO di Crossfire Medical.
Il vasto background del Dr. Egeland include posizioni di leadership in Cardiovascular Systems, Inc., Medtronic, Covidien e ev3. Possiede un M.D. presso la Harvard Medical School, un Ph.D. e un M.B.A. dall'Università di Oxford come Rhodes Scholar, e si è formato in chirurgia plastica e ricostruttiva presso il Northwestern Memorial Hospital. Solventum mira a sfruttare l'esperienza del Dr. Egeland per far progredire il proprio pipeline d'innovazione e migliorare le cure ai pazienti a livello globale.
Solventum (NYSE: SOLV) ha nombrado al nuevo Director Médico, Dr. Ryan Egeland, MD. El Dr. Egeland liderará el equipo de Asuntos Médicos y Clínicos Globales, centrándose en mejorar la voz de los clínicos y los pacientes, fomentando la colaboración en la industria e identificando oportunidades de innovación. Aporta más de 20 años de experiencia en investigación, cirugía y roles ejecutivos, habiendo sido más recientemente CEO de Crossfire Medical.
El amplio historial del Dr. Egeland incluye puestos de liderazgo en Cardiovascular Systems, Inc., Medtronic, Covidien y ev3. Tiene un M.D. de la Harvard Medical School, un Ph.D. y un M.B.A. de la Universidad de Oxford como Rhodes Scholar, y se formó en cirugía plástica y reconstructiva en el Northwestern Memorial Hospital. Solventum busca aprovechar la experiencia del Dr. Egeland para avanzar en su pipeline de innovación y mejorar la atención al paciente a nivel mundial.
솔벤텀 (NYSE: SOLV)은 새로운 최고 의학 책임자로 Dr. Ryan Egeland, MD를 임명했습니다. Egeland 박사는 글로벌 의학 및 임상 업무 팀을 이끌며 클리닉과 환자의 목소리를 강화하고, 산업 협력을 촉진하며, 혁신 기회를 찾는 데 집중할 것입니다. 그는 연구, 수술 및 경영 역할에서 20년 이상의 경험을 보유하고 있으며, 최근에는 Crossfire Medical의 CEO로 재직했습니다.
Egeland 박사의 폭넓은 배경은 Cardiovascular Systems, Inc., Medtronic, Covidien 및 ev3에서의 리더십 역할을 포함합니다. 그는 Harvard Medical School에서 M.D.를 받았고, 옥스퍼드 대학교에서 Ph.D. 및 M.B.A.를 로즈 장학생으로 취득했으며, Northwestern Memorial Hospital에서 성형 및 재건 수술을 교육받았습니다. 솔벤텀은 Egeland 박사의 전문 지식을 활용하여 혁신 파이프라인을 발전시키고 전 세계적으로 환자 치료를 개선하고자 합니다.
Solventum (NYSE: SOLV) a nommé Dr. Ryan Egeland, MD en tant que nouveau Directeur Médical. Le Dr. Egeland dirigera l'équipe des affaires médicales et cliniques mondiales, se concentrant sur l'amélioration de la voix des cliniciens et des patients, favorisant la collaboration dans l'industrie et identifiant les opportunités d'innovation. Il apporte plus de 20 ans d'expérience dans la recherche, la chirurgie et des rôles exécutifs, servant récemment en tant que PDG de Crossfire Medical.
Le vaste parcours du Dr. Egeland comprend des postes de direction chez Cardiovascular Systems, Inc., Medtronic, Covidien et ev3. Il possède un M.D. de la Harvard Medical School, un Ph.D. et un M.B.A. de l'Université d'Oxford en tant que Rhodes Scholar, et il s'est formé en chirurgie plastique et reconstructive au Northwestern Memorial Hospital. Solventum vise à tirer parti de l'expertise du Dr. Egeland pour faire avancer son pipeline d'innovation et améliorer les soins aux patients à l'échelle mondiale.
Solventum (NYSE: SOLV) hat Dr. Ryan Egeland, MD zum neuen Chief Medical Officer ernannt. Dr. Egeland wird das Team für globale medizinische und klinische Angelegenheiten leiten und sich darauf konzentrieren, die Stimme der Kliniker und Patienten zu stärken, die Zusammenarbeit in der Branche zu fördern und Innovationsmöglichkeiten zu identifizieren. Er bringt über 20 Jahre Erfahrung in Forschung, Chirurgie und Führungspositionen mit, zuletzt als CEO von Crossfire Medical.
Der umfangreiche Hintergrund von Dr. Egeland umfasst Führungspositionen bei Cardiovascular Systems, Inc., Medtronic, Covidien und ev3. Er hat einen M.D. von der Harvard Medical School, einen Ph.D. und einen M.B.A. von der Universität Oxford als Rhodes Scholar und hat sich in plastischer und rekonstruktiver Chirurgie am Northwestern Memorial Hospital fortgebildet. Solventum zielt darauf ab, das Fachwissen von Dr. Egeland zu nutzen, um seine Innovationspipeline voranzutreiben und die Patientenversorgung weltweit zu verbessern.
- Appointment of experienced Chief Medical Officer with over 20 years in research, surgery, and executive roles
- Potential for enhanced innovation and market expansion opportunities
- Dr. Egeland's diverse background in medical devices and healthcare companies
- None.
Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group president, Medical Surgical, Solventum.
"We are pleased to welcome Dr. Egeland to Solventum. With over two decades of experience in the research lab, operating room, and executive settings, his extensive experience and proven track record in clinical development strategy and execution will be invaluable as we advance our innovation pipeline and enhance patient care around the world," said Barry.
Dr. Egeland joins Solventum from Crossfire Medical, where he has been Chief Executive Officer since 2022. Previously, he served as the Head of Strategic Ventures and Chief Medical Officer for Cardiovascular Systems, Inc. (CSI). Prior to his tenure at CSI, Dr. Egeland led teams in Business Development & Licensing, Medical & Scientific Affairs, and Product Marketing at Medtronic, Covidien, and ev3.
"I am thrilled to join Solventum. With products that offer profound clinical benefits and solutions that enhance provider efficiency and impact, we have a rare opportunity to help our customers enhance the patient experience and improve lives," said Dr. Egeland. "Through partnership, innovation, and dedication to the patients we serve Solventum and our customers, together, will shape the future of healthcare."
Dr. Egeland earned his M.D. from Harvard Medical School and was a Rhodes Scholar at the University of Oxford, where he completed his Ph.D. and M.B.A. He trained in plastic and reconstructive surgery at Northwestern Memorial Hospital and has worked in major academic hospitals and private clinics. He is a Board Member of Piraeus Medical and Vergent Bioscience.
About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-names-surgeon-and-diagnostics-pioneer-dr-ryan-egeland-as-chief-medical-officer-302270823.html
SOURCE Solventum
FAQ
Who is the new Chief Medical Officer of Solventum (NYSE: SOLV)?
What are Dr. Ryan Egeland's responsibilities as Solventum's (NYSE: SOLV) Chief Medical Officer?
What is Dr. Ryan Egeland's educational background?
What was Dr. Ryan Egeland's most recent position before joining Solventum (NYSE: SOLV)?
